2020
DOI: 10.1016/j.ijid.2019.12.004
|View full text |Cite
|
Sign up to set email alerts
|

Do genetic polymorphisms of B-cell CLL/lymphoma 2 confer susceptibility to anti-tuberculous therapy-associated drug-induced liver injury?

Abstract: The aim of this study was to identify the relationship between B-cell CLL/lymphoma 2 (BCL2) polymorphisms and susceptibility to anti-tuberculous therapy-associated drug-induced liver injury (ATT-DILI). Methods: A total of 746 tuberculosis (TB) patients were enrolled in this study. Twenty-one selected single nucleotide polymorphisms in BCL2 were analyzed by custom-by-design 2 Â 48-Plex SNPscan kit. The allele and genotype frequencies between patients with and without ATT-DILI were compared using three different… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 50 publications
0
1
0
Order By: Relevance
“…Lyu et al . 22 showed that BCL2 variants may be associated with drug-induced liver injury associated with anti-tuberculous therapy. There is an interaction between BCL2 and glutathione, an important regulator of lung inflammation, and restoration of BCL2 expression leads to the replenishment of glutathione and a reduction in the levels of reactive oxygen species 23 .…”
Section: Discussionmentioning
confidence: 99%
“…Lyu et al . 22 showed that BCL2 variants may be associated with drug-induced liver injury associated with anti-tuberculous therapy. There is an interaction between BCL2 and glutathione, an important regulator of lung inflammation, and restoration of BCL2 expression leads to the replenishment of glutathione and a reduction in the levels of reactive oxygen species 23 .…”
Section: Discussionmentioning
confidence: 99%